Helix Biopharma to Present L-DOS47 Lung Cancer Research Findings at the Fourth International Conference on Tumor Microenvironment in Florence, Italy

    AURORA, ON, March 5 /CNW/ - Helix BioPharma Corp. (TSX: HBP /
Frankfurt: WKN 918864)
    Dr. Heman Chao, Vice President of Research at Helix BioPharma Corp., a
developer of novel cancer therapeutics, will be presenting a scientific poster
at the Fourth International Conference on Tumor Microenvironment, which runs
from March 6th to 10th in Florence, Italy.
    The conference, hosted by the International Cancer Microenvironment
Society, is a premier gathering of international cancer researchers who seek
to develop cancer therapies targeting microenvironmental factors that control
tumor growth and metastasis.
    The poster, titled "L-DOS47 - a tumor microenvironment alkalization agent
and a novel lung adenocarcinoma specific therapeutic candidate," provides a
summary of selected L-DOS47 previously announced findings. Included in the
poster are laboratory data showing the ability of L-DOS47 to bind to and
destroy lung cancer cells alone and synergistically with selected
chemotherapeutic drugs. Also being presented are mass tissue sample screening
data, which show that L-DOS47 binds not only to primary lung adenocarcinoma
tissues preferentially over a host of other cancerous or normal tissues, but
also to metastasized cells in lymph nodes. The poster also highlights the
ability of L-DOS47 to localize and concentrate in tumor tissues specifically
following injection into laboratory animals
    A copy of the poster will be available on Helix's website for download at
    For additional information on the Tumor Microenvironment conference,
please visit http://cancermicroenvironment.tau.ac.il/meeting-2007.html

    About L-DOS47

    L-DOS47 combines Helix's proprietary DOS47 new drug candidate with a
highly specific single domain antibody, to form a potential new targeted drug
product for the treatment of adenocarcinoma of the lung, the most common form
of cancer in the world today. L-DOS47 is thought to function by leveraging a
natural process in the body called the urea cycle, to produce an anti-cancer
effect. It is based upon a naturally occurring enzyme called urease that
essentially reverses the urea cycle by breaking down urea into metabolites
that include ammonia and hydroxyl ions. By doing so at the site of cancerous
tissues in the body, L-DOS47 is believed to modify the microenvironmental
conditions of lung cancer cells in a manner that leads to their death. Among
these theorized effects, L-DOS47 is believed to stimulate an increase in the
pH of the microenvironment surrounding the cancerous cells, effectively
reversing the acidic extra-cellular conditions that are known to be necessary
for cancer cell survival. As well, the local production of ammonia at the site
of cancerous tissues is thought to readily diffuse into the cancer cells to
exert a potent cytotoxic effect by interfering with their critical metabolic

    About Helix BioPharma Corp.

    Helix BioPharma Corp. is a biopharmaceutical company specializing in the
field of cancer therapy. The Company is actively developing innovative
products for the prevention and treatment of cancer based on its proprietary
technologies. Helix's product development initiatives include its Topical
Interferon Alpha-2b, for the treatment of conditions caused by the human
papilloma virus, and its novel L-DOS47 new drug product candidate for the
treatment of lung adenocarcinoma. Helix is listed on the TSX under the symbol

    The Toronto and Frankfurt Stock Exchanges have not reviewed and do not
accept responsibility for the adequacy or accuracy of the content of this News
Release. Helix disclaims responsibility for information contained in the Tumor
Microenvironment conference website, and the reference to such website in this
News Release does not constitute an endorsement by Helix of that or any other
website. This News Release contains certain forward-looking statements
regarding potential cancer therapeutics under development by the Company, and
in particular, regarding L-DOS47. Forward-looking statements can be identified
by the use of forward-looking terminology such as "potential", "is thought",
"is believed", "new", "will", "theorized", or variations thereon or comparable
terminology referring to future events or results. Forward looking statements
are statements about the future and are inherently uncertain, and Helix's
actual results could differ materially from those anticipated in these
forward-looking statements as a result of numerous factors, including without
limitation, uncertainty whether L-DOS47 will be developed successfully as a
drug or at all; uncertainty whether DOS47 will be developed as a therapeutic
for any other cancers; research & development risks, including the risk that
early R&D results may not be repeated in later R&D; the risk of technical
obsolescence; the need for regulatory approvals, which may not be obtained in
a timely matter or at all; the need for clinical trials, the occurrence and
success of which cannot be assured; intellectual property risks;
marketing/manufacturing and partnership/strategic alliance risks; the effect
of competition; Helix's need for additional future capital, which may not be
available in a timely manner or at all, as well as a description of other
risks and uncertainties affecting Helix and its business, as contained in
Helix's latest Annual Information Form and other filings with the Canadian
Securities Regulatory Authorities at www.sedar.com, any of which could cause
actual results to vary materially from current results or Helix's anticipated
future results. Forward-looking statements are based on the beliefs, opinions
and expectations of Helix's management at the time they are made, and Helix
does not assume any obligation to update any forward-looking statement should
those beliefs, opinions or expectations, or other circumstances change.

For further information:

For further information: Investor Relations, Christina Bessant, The
Equicom Group Inc., Tel: (416) 815-0700 ext. 269, (800) 385-5451, Fax: (416)
815-0080, Email: cbessant@equicomgroup.com; Media Relations, Matthew Haines,
Noonan Russo, Tel: (212) 845-4235, Fax: (212) 845-4260, Email:
Matthew.Haines@eurorscg.com, www.NoonanRusso.com

Organization Profile


More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890